Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/35437
Title: | Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? |
Authors: | GIRARDI, Daniel M.; FARIA, Luiza Dib B. B.; TEIXEIRA, Marcela C.; COSTA, Frederico P.; HOFF, Paulo Marcelo G.; FERNANDES, Gustavo S. |
Citation: | JOURNAL OF GASTROINTESTINAL CANCER, v.50, n.4, p.860-866, 2019 |
Abstract: | Purpose Advanced pancreatic adenocarcinoma (PA) is an aggressive disease that has poor prognosis and frequently interferes with patient's quality of life. There has been progress in first-line regimens; however, there is no standard second-line regimen. The aim of this study is to analyze second-line gemcitabine after first-line fluorouracil (FU) + leucovorin (LV) + irinotecan + oxaliplatin (FOLFIRINOX) regimen. Methods This study included consecutive patients with advanced PA treated at Hospital Sirio-Libanes from 2011 to 2016. The patients received FOLFIRINOX as first-line treatment and upon progression, received gemcitabine alone. Survival analysis was performed using the Kaplan-Meier method. Results A total of 54 patients were evaluated. Most patients were male (61.1%) and most had an ECOG performance status of 0 or 1 prior to the beginning of second-line treatment (66.6%). The mean number of gemcitabine cycles was 3.4. Most patients had disease progression as the best response to treatment (75.9%), 11.1% had stable disease, and 9.3% experienced a partial response. The median progression-free survival was 1.7 months, and the median overall survival was 6.8 months. Conclusions Gemcitabine alone did not show meaningful clinical benefit as second-line treatment after FOLFIRINOX. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MDR Artigos e Materiais de Revistas Científicas - LIM/24 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_GIRARDI_SecondLine_Treatment_for_Advanced_Pancreatic_Adenocarcinoma_Is_There_2019.PDF.pdf Restricted Access | publishedVersion (English) | 627.71 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.